Physician profile
Mohammad T Al Assi
NPI 1578554333
$3,052.94
in general payments reported to CMS, 2019-2025
37 companies · $542 in 2025
The $542 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $53.23 · 2022: $427 · 2023: $742 · 2024: $686 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955 · Education: $14.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.39 |
| Education | $14.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $390.03 | 2019 | |
| Abbvie INC. | $373.36 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $319.51 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $271.03 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $262.60 | 2020-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $175.42 | 2024-2025 | Omvoh |
| Shionogi INC | $139.26 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.88 | 2022-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $118.50 | 2023-2024 | Dupixent |
| Ardelyx, INC. | $104.41 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.90 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $63.97 | 2022-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $61.70 | 2022-2023 | Dificid |
| Celltrion USA INC. | $60.16 | 2023-2025 | Vegzelma, Yuflyma |
| Phathom Pharmaceuticals, INC. | $59.62 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $58.70 | 2023 | Agile Esophageal |
| Daiichi Sankyo INC. | $55.50 | 2022-2023 | Injectafer |
| Aimmune Therapeutics, INC. | $51.96 | 2024 | |
| Intercept Pharmaceuticals, INC. | $48.71 | 2022-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $35.08 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $31.11 | 2025 | Iqirvo |
| Pinnacle Biologics, INC | $27.98 | 2025 | Photofrin |
| Fresenius Kabi USA, LLC | $26.75 | 2024 | Idacio |
| Ironwood Pharmaceuticals, INC | $22.22 | 2023 | Linzess |
| Evoke Pharma, INC. | $17.72 | 2022 | |
| Vivus LLC | $16.68 | 2024 | Qsymia |
| Capsovision, INC. | $16.41 | 2023 | Capsocam Plus |
| Braintree Laboratories, INC. | $16.33 | 2022 | |
| Enterra Medical, INC. | $15.67 | 2024 | |
| Organon LLC | $14.96 | 2023 | Hadlima |
| Allergan, INC. | $11.81 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,123.46 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Al Assi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.